Taspoglutide: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: moderate
- โข4 research gaps identified
Research Studies
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 Trial
Nauck MA, Stewart MW, Perkins C, et al. (2013) โข Diabetes Care
Phase 3 trial comparing taspoglutide 10 mg and 20 mg weekly to exenatide 10 mcg twice daily in overweight adults with inadequately controlled T2D on metformin. Taspoglutide demonstrated superior glycemic control but unacceptable tolerability.
Key Findings
- HbA1c reduction: taspoglutide 20 mg -1.31% vs exenatide -0.98% (P<0.0001)
- HbA1c reduction: taspoglutide 10 mg -1.24% vs exenatide -0.98% (P<0.0001)
- Weight loss: taspoglutide 20 mg -2.3 kg, comparable to exenatide -2.3 kg
- Nausea: taspoglutide 10 mg 53%, 20 mg 59%, exenatide 35%
- Vomiting: taspoglutide 10 mg 33%, 20 mg 37%, exenatide 16%
- Anti-taspoglutide antibodies detected in 49% of patients
Limitations: Open-label design for exenatide arm; trial terminated before planned completion due to safety concerns; high discontinuation rates limit long-term efficacy assessment
Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
Bergenstal RM, Forti A, Chiasson JL, et al. (2012) โข Diabetes Therapy
Phase 3 trial comparing taspoglutide to sitagliptin 100 mg daily in T2D patients on metformin. Taspoglutide demonstrated superior glycemic control and weight loss but with high adverse event rates leading to high discontinuation.
Key Findings
- Taspoglutide demonstrated superior HbA1c reduction compared to sitagliptin
- Greater weight loss with taspoglutide versus sitagliptin
- High incidence of gastrointestinal adverse events with taspoglutide
- High discontinuation rates due to adverse events
Limitations: High discontinuation rates in the taspoglutide arm limit interpretation; development was halted before long-term outcomes could be assessed
Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment (T-emerge 1)
Rosenstock J, Balas B, Charbonnel B, et al. (2013) โข Diabetes Care
Phase 3 monotherapy trial of taspoglutide in treatment-naive T2D patients. Demonstrated significant glycemic improvement as monotherapy but with characteristic GI side effect profile.
Key Findings
- Significant HbA1c reduction versus placebo as monotherapy
- Weight loss observed with taspoglutide treatment
- GI adverse events consistent with the T-emerge program
- Antibody formation consistent with other T-emerge trials
Limitations: Monotherapy population may not generalize to more advanced T2D requiring combination therapy; development halted before long-term follow-up
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 5+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขLong-term efficacy and safety data were never obtained due to early program termination
- โขCardiovascular outcomes were never assessed (no dedicated CVOT was conducted or planned)
- โขWhether formulation modifications could have addressed immunogenicity was not explored
- โขHead-to-head comparisons with modern GLP-1 agonists (semaglutide, dulaglutide) were never conducted
Research Overview#
Taspoglutide was evaluated in the T-emerge phase 3 clinical trial program, a multi-study effort designed to establish efficacy and safety across various type 2 diabetes populations. The program included at least five major trials: T-emerge 1 (monotherapy), T-emerge 2 (vs exenatide), T-emerge 3 (vs insulin glargine), T-emerge 4 (vs sitagliptin), and T-emerge 5 (with insulin glargine).
The evidence level is classified as moderate because while the trials were large, randomized, and controlled, the program was terminated prematurely, limiting the completeness of the dataset and preventing assessment of long-term outcomes.
T-emerge Clinical Trial Program#
T-emerge 1: Monotherapy#
T-emerge 1 (Rosenstock et al., 2013; PMID 22301126) evaluated taspoglutide as monotherapy in treatment-naive T2D patients over 24 weeks. Taspoglutide demonstrated significant HbA1c reduction compared to placebo, establishing its glucose-lowering efficacy as a standalone agent. However, the GI adverse event profile was consistent with the broader T-emerge program.
T-emerge 2: Versus Exenatide#
T-emerge 2 (Nauck et al., 2013; PMID 23139373) was the most informative trial, directly comparing taspoglutide (10 mg and 20 mg weekly) to exenatide (10 mcg twice daily) in 1,189 overweight adults with T2D on metformin.
Key efficacy results:
- HbA1c reduction: taspoglutide 20 mg -1.31% versus exenatide -0.98% (P<0.0001)
- HbA1c reduction: taspoglutide 10 mg -1.24% versus exenatide -0.98% (P<0.0001)
- Both taspoglutide doses were statistically superior to exenatide for glycemic control
- Weight loss was comparable: taspoglutide 20 mg -2.3 kg, exenatide -2.3 kg
Key safety results:
- Nausea: 53% (10 mg), 59% (20 mg) vs 35% (exenatide)
- Vomiting: 33% (10 mg), 37% (20 mg) vs 16% (exenatide)
- Anti-taspoglutide antibodies: detected in 49% of patients
- Injection-site reactions: significantly more common with taspoglutide
- Systemic allergic reactions: reported with taspoglutide but not exenatide
T-emerge 4: Versus Sitagliptin#
T-emerge 4 (Bergenstal et al., 2012; PMID 23138449) compared taspoglutide to sitagliptin 100 mg daily. Taspoglutide demonstrated superior glycemic control and weight loss, but the high adverse event rate and discontinuation rates undermined the clinical value.
Program Termination#
In September 2010, Roche made the decision to halt all taspoglutide phase 3 trials and subsequently returned the compound to Ipsen. The primary drivers were:
- Gastrointestinal toxicity: Nausea and vomiting rates far exceeded those of comparator GLP-1 agonists
- Immunogenicity: Anti-drug antibody formation in 49% of patients, associated with injection-site and systemic allergic reactions
- Hypersensitivity: Serious systemic allergic reactions that were not observed with other GLP-1 agonists
- High discontinuation: Adverse event-driven dropouts compromised the clinical utility of the drug
Lessons for GLP-1 Development#
Taspoglutide's failure provided important lessons for the GLP-1 agonist field:
- Formulation matters: Zinc-based depot formulations may increase immunogenicity compared to acylation (semaglutide) or albumin fusion (albiglutide) strategies
- Immunogenicity screening: The importance of monitoring anti-drug antibodies was reinforced
- GI tolerability ceiling: Even highly effective GLP-1 agonists are clinically unusable if GI side effects are intolerable
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | Phase 3 RCTs | Multiple trials in the T-emerge program |
| Sample size | Large (n>1,000 in key trials) | Adequate for efficacy assessment |
| Active comparator | Yes | vs exenatide, sitagliptin, insulin glargine |
| Program completion | Terminated early | Safety-driven program halt |
| Regulatory status | Never approved | Development discontinued 2010 |
| Long-term data | Not available | Program terminated before long-term follow-up |
| Safety database | Sufficient for signal detection | Immunogenicity and GI toxicity clearly identified |
Related Reading#
Frequently Asked Questions About Taspoglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.